*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**King International Investment Limited**

**帝王國際投資有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 928)**

# APPOINTMENT OF EXECUTIVE DIRECTOR AND CO-CHAIRMAN OF THE BOARD

The Board (the "**Board**") of Directors (the "**Directors**") of King International Investment Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Mr. Wang Jun (王軍) ("**Mr. Wang**") has been appointed as an executive Director and the Co-chairman with effect from 4 December 2025.

## APPOINTMENT OF EXECUTIVE DIRECTOR AND CO-CHAIRMAN

The Board is pleased to announce that Mr. Wang will be appointed as an executive Director and the Co-chairman with effect from 4 December 2025.

The biographical details of Mr. Wang are set out below:

Mr. Wang Jun (王軍), aged 57, possesses extensive professional experience in management. As the founder and chairman of the board of Bio Holdings Group* (拜奧控股集團), he is primarily responsible for formulating the Bio Holdings Group's overall development strategy, technological Research & Development roadmap, and capital operation plans. Mr. Wang possesses over twenty years of experience in biotechnology, regenerative medicine, and international financial capital markets. He is a global pioneer in the concepts of "life asset management" and "financialisation of life data".

Mr. Wang possesses a profound academic background with deep collaborative ties to Nankai University and Tsinghua University. He co-founded Shenzhen Xin'an Jin Biotechnology Co., Ltd.*(深圳新安津生物科技有限公司) with the School of Life Sciences at Nankai University, dedicated to the research and development of tumour organoids and universal tumour vaccines. He has spearheaded the translation of multiple cutting-edge biotechnologies. As an entrepreneur with a scientific background, Mr. Wang is a leading figure in induced pluripotent stem cells (iPSC) and regenerative medicine. He personally spearheaded the breakthroughs in core technical bottlenecks for seed cell preparation and genomic stability, but also holds over 30 national invention patents and international PCT patents covering comprehensive systems including cardiac muscle, nerves, pancreas, and blood vessels as the first inventor. His recently approved patents cover breakthrough applications of iPSC in critical areas such as pancreatic islet progenitor cell repair, vascular endothelial progenitor cell differentiation, and combined therapies for cardiovascular and cerebrovascular diseases. He maintains a long-term and close scientific collaboration with the Research Institute of Tsinghua University in Shenzhen, jointly establishing the "Digital R&D Centre for Traditional Chinese Medicine of Research Institute of Tsinghua University in Shenzhen," dedicated to developing application systems that deeply combine artificial intelligence with traditional Chinese medicine culture. The "Centre for Enterprise Management and Financial Innovation of Research Institute of Tsinghua University in Shenzhen" is dedicated to building an innovative life and health ecosystem financial neural network system.

In business and capital operations, Mr. Wang has demonstrated exceptional international vision. He initiated the international exploration of healthcare in 2009 and pioneered the introduction and localisation of the United States "Know Your Number" health data system in 2010, laying the early foundation for Bio Group*(拜奧集團)'s data-driven mindset. In 2016, Mr. Wang founded Yubo International Biotechnology (Beijing) Group Co., Ltd.*(羽鉑國際生物科技(北京)集團有限公司), developing the "Vivicell" product portfolio centred on endometrial stem cells. He successfully guided the company to list on the United States capital market (Pink Sheets) in 2020, and subsequently upgraded it to the OTCQB Market in 2023, charting a strategic roadmap for transitioning to the NASDAQ main board.

Currently, Mr. Wang is dedicated to building a multi-omics AI model based on data from a population of 1.4 billion and has pioneered a life data asset custody model using a "financial nervous system" as its underlying tool. He integrates the "Bio Life*(拜奧生命)" and "Paike Taisu*(派科泰素)" networks of over 10,000 offline clinics to advance the tokenization of physical healthcare rights and benefits, building an online-offline integrated financial-grade life and health ecosystem.

Mr. Wang's joining has brought critical industry insights and resource integration capabilities to the Company's development in the healthcare sector, significantly enhancing the Company's market competitiveness and future growth potential.

As at the date of this announcement, Mr. Wang does not (i) hold any other position in the Company and other members of the Group; (ii) hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) hold any other major appointments and professional qualifications.

As at the date of this announcement, Mr. Wang has no relationships with any Director, senior management, substantial or controlling shareholders (having the meaning ascribed to it in the Rules Governing the Listing of Securities (the "**Listing Rules**") on the Stock Exchange) of the Company and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Under the service contract entered into between Mr. Wang and the Company, his term of service is 3 years. His directorship with the Company shall be subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Mr. Wang's remuneration is HK$120,000 per year, which is determined by the Board and the Remuneration Committee with reference to his experience, duties and level of responsibilities within the Company.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Wang that need to be brought to the attention of the shareholders of the Company, and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express a warm welcome to Mr. Wang for joining the Company.

By order of the Board
**King International Investment Limited**
**Wang Mengyao**
*Executive Director*

Hong Kong, 4 December 2025

As at the date of this announcement, the Board comprises:

*Executive Directors:*
Mr. Leng Yueyingtan *(Co-chairman)*
Mr. Wong Jun *(Co-chairman)*
Mr. Wang Mengyao
Mr. Man Wai Lun
Mr. Li Li

*Independent non-executive Directors:*
Mr. Lou Tao
Mr. Wang Zhenyu
Mr. Liu Zhong

* *For identification purposes only*

* *The English translation of the Chinese name is for information purpose only and should not be regarded as the official English translation of such Chinese name.*

If there is any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.